WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Merck Group

MerckMerck is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses - Merck Serono, Consumer Health, Allergopharma, Biosimilars, Merck Millipore and Performance Materials - and generated sales of € 11.3 billion in 2014. Around 39,000 Merck employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck is the world's oldest pharmaceutical and chemical company - since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.

www.merckgroup.com

Merck KGaA RSS Channel

Filters
List of articles in category Merck Group
Title Published Date
Merck announces recipients of €1 million Grant for Multiple Sclerosis Innovation at ECTRIMS 2017 26 October 2017
Merck brings customers closer to gene therapy product commercialization 19 October 2017
Merck set to join forces with Project Data Sphere to pioneer Global Oncology Big Data Alliance 11 September 2017
Merck collaborates with angiex to speed clinical readiness of new cancer therapy 29 August 2017
Merck Biopharma Innovation Cup 2017 17 July 2017
Merck awards €1.25 million to research projects through its 2017 Grant for Fertility Innovation (GFI) 05 July 2017
Merck Foundation established 22 June 2017
Merck Ventures creates new immuno-oncology company iOnctura 20 June 2017
Anyone can become more curious. Is that true? 31 May 2017
100 healthy years - are kids prepared? 19 May 2017
Merck acquires Grzybowski Scientific Inventions to expand chemical synthesis offering 09 May 2017
Merck divests Biosimilars business to Fresenius 25 April 2017
Merck partners with University of California, San Diego (UCSD) to fight Neglected Tropical Diseases 20 April 2017
Merck advances R&D strategy through unique development model with Avillion for Anti IL-17 A/F Nanobody 30 March 2017
Merck Accelerator hits new peak of applications 21 March 2017
Cladribine tablets significantly reduced brain atrophy in patients with multiple sclerosis 09 February 2017
Merck announces research collaboration with Domain Therapeutics in immuno-oncology 23 January 2017
Merck drives business opportunities in the U.S. to foster innovation across all three business sectors 13 January 2017
Merck wins R&D 100 Award for top invention 11 November 2016
Merck invests € 250 million in production value chain in China 04 November 2016
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next
  • End
Tahmeena

Business & Industry

  • AMJEVITA™ (adalimumab-atto), first biosimilar to Humira® now available in the United States
  • CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
  • Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
  • Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries
  • Acquisition of Neogene Therapeutics completed

Research & Development

  • Antidepressants used for chronic pain on the rise, but are they effective?
  • Keys to making immunotherapy work against pancreatic cancer found in tumor microenvironment
  • Discovery of anti-cancer chemistry makes skullcap fit for modern medicine
  • Coordination of COVID-19 vaccine clinical trials produces a 'treasure trove' of data and a model for the future
  • Power of cancer drugs may see boost by targeting newly ID'd pathway
  • A soybean protein blocks LDL cholesterol production, reducing risks of metabolic diseases
  • 500,000 missed out on blood pressure lowering drugs during pandemic

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. Merck Group
  4. Merck partners with Medisafe to help improve medication adherence for cardiometabolic patients

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.